Published in J Immunother on June 19, 2008
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater (2012) 1.40
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Spaceflight effects on T lymphocyte distribution, function and gene expression. J Appl Physiol (1985) (2008) 1.16
A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res (2012) 1.14
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res (2015) 1.05
Induction of apoptosis by 11-dehydrosinulariolide via mitochondrial dysregulation and ER stress pathways in human melanoma cells. Mar Drugs (2012) 1.00
miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci U S A (2014) 0.87
Cutaneous Melanoma in Asians. Chonnam Med J (2016) 0.86
Proteomic investigation of the sinulariolide-treated melanoma cells A375: effects on the cell apoptosis through mitochondrial-related pathway and activation of caspase cascade. Mar Drugs (2013) 0.85
Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of low systemic toxicity. Cancer Immunol Immunother (2012) 0.83
Comparison of vascular leak syndrome in mice treated with IL21 or IL2. Comp Med (2013) 0.80
Nanoparticle immunotherapy: Combo combat. Nat Mater (2012) 0.79
Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol (2015) 0.77
The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma. J Adv Pract Oncol (2015) 0.75
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer (2016) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Long-term effects of hormone therapy on skin rigidity and wrinkles. Fertil Steril (2005) 2.77
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Cadaveric study of breast measurements during augmentation with implants. Plast Reconstr Surg (2015) 2.34
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13
Infantile hemangiomas exhibit neural crest and pericyte markers. Ann Plast Surg (2015) 2.12
Advances in the systemic treatment of metastatic melanoma. Oncology (Williston Park) (2013) 2.05
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (2011) 1.99
Recent advances in postoperative pain management. Yale J Biol Med (2010) 1.89
Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol (2006) 1.85
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology (2010) 1.71
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res (2007) 1.57
Human skin-color sexual dimorphism: a test of the sexual selection hypothesis. Am J Phys Anthropol (2007) 1.56
Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceus. J Invest Dermatol (2012) 1.50
Microarray gene analysis and expression profiles of Dupuytren's contracture. Ann Plast Surg (2003) 1.45
Cadaveric allograft for wound closure after resection of squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a report of 32 resections and repairs in 2 patients. Ann Plast Surg (2009) 1.44
Benefits and Risks of Prophylaxis for Deep Venous Thrombosis and Pulmonary Embolus in Plastic Surgery: A Systematic Review and Meta-Analysis of Controlled Trials and Consensus Conference. Plast Reconstr Surg (2016) 1.41
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther (2003) 1.40
A proposal for the timing of management of patients with melanoma presenting during pregnancy. J Surg Oncol (2012) 1.40
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39
Functional Neck Dissection: The Operative Technique Series. Plast Reconstr Surg (2016) 1.39
Cellularity and adipogenic profile of the abdominal subcutaneous adipose tissue from obese adolescents: association with insulin resistance and hepatic steatosis. Diabetes (2010) 1.35
Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol (2009) 1.33
Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2014) 1.30
A role for ATF2 in regulating MITF and melanoma development. PLoS Genet (2010) 1.28
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res (2011) 1.27
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res (2003) 1.24
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res (2005) 1.22
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med (2007) 1.21
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol (2004) 1.16
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol (2004) 1.14
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res (2005) 1.13
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res (2003) 1.13
Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res (2011) 1.12
Thoracic esophageal perforations. South Med J (2003) 1.11
PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell (2012) 1.11
Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther (2007) 1.09
Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol (2009) 1.08
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res (2004) 1.08
A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer. PLoS One (2013) 1.08
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest (2008) 1.07
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02
Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies. BMC Genomics (2011) 1.02
Microsurgical free flap reconstruction outcomes in head and neck cancer patients after surgical extirpation and intraoperative brachytherapy. Laryngoscope (2004) 1.02
Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma. J Am Coll Surg (2002) 1.01
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res (2006) 1.01
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res (2006) 1.00
Ipilimumab-induced perforating colitis. J Clin Gastroenterol (2013) 1.00
How many patients with infrarenal aneurysms are candidates for endovascular repair? The Northern California experience. J Endovasc Ther (2004) 0.99
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Rab33A: characterization, expression, and suppression by epigenetic modification. J Invest Dermatol (2006) 0.98
Traumatic frontal bone fracture resulting in intracerebral pneumocephalus. J Craniofac Surg (2005) 0.97
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res (2009) 0.97
Use of the operating microscope and loupes for head and neck free microvascular tissue transfer: a retrospective comparison. Arch Otolaryngol Head Neck Surg (2003) 0.97
Centrosomal Chk2 in DNA damage responses and cell cycle progression. Cell Cycle (2010) 0.95
Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod Pathol (2008) 0.94
Merkel cell carcinoma: five case reports using sentinel lymph node biopsy and a review of 110 new cases. Plast Reconstr Surg (2002) 0.93
Giant nevi: a review. J Craniofac Surg (2006) 0.93
Prosthetic vascular graft infection: a multi-center review of surgical management. Yale J Biol Med (2007) 0.93
USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains. J Biol Chem (2011) 0.91
Squamous cell carcinoma in a linear epidermal nevus. J Plast Reconstr Aesthet Surg (2008) 0.91
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res (2005) 0.90
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol (2005) 0.90